PlainPatent
USPTO 2015–2025 USPTO PatentsView US Corporation

Aneira Pharma, Inc.

USPTO PatentsView assignee record - 10 granted patents across 3 technology areas, recorded in grant years 2021–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

RSS updates for this company
Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Aneira ranks #25,739 of 49,997 tracked US assignees by granted-patent volume, with 10 patents across 3 technology areas.

#25,739
of 49,997 US assignees by volume
Top 33%
by Innovation Score (41.5/100)
23.0
avg claims per patent

USPTO PatentsView assignee plate

Corpus R25739 · US Corporation #25,739 · 10 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-DENSE · TYPE-USCORP · SPAN-YRS · BOOK-RICH

  • GRANTS-MICRO 10 grants
  • MID-PACK #25,739/49,997
  • PHOTO-FINISH Amylyx Pharmaceuticals
  • CPC-NARROW A61P · 3 areas
  • INNOV-PAR 41.5/100
  • CLAIMS-DENSE 23.0 claims/avg
  • TYPE-USCORP US Corporation
  • SPAN-YRS 2021–2025 · 5y
  • BOOK-RICH 9/10 fields

Nearest grant-volume peer: Amylyx Pharmaceuticals, Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Aneira’s 41.5 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Innovation-score neighbourhood around Aneira

Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.

score

What this shows Aneira's Innovation Score is 41.5/100 (top 33% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Source USPTO PatentsView, PlainPatent Innovation Score As of 2015–2025

Does more volume mean deeper claims for Aneira?

Each dot is one of Aneira’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Aneira’s own 23.0 claims/patent is ABOVE the 18.4 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Aneira vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView. 2×2 strategic matrix plotting 9 entities by Granted patents (volume) (X) and Avg claims / patent (Y), with a crosshair dividing the plot into four quadrants. Volume + depthSelective & thoroughVolume over depthLean filer 9.99.91010.1 10152025 Granted patents (volume) Avg claims / patent Amylyx Pharmaceuticals, Inc. - 10, 17.5Amylyx Pharmaceut…Analytical Mechanics Associates, Inc. - 10, 18.4Analytical Mechan…Anchor Ring Solutions, LLC - 10, 19.6Anchor Ring Solut…Andax Industries, L.L.C. - 10, 20.9Andax Industries…Anomali Incorporated - 10, 19.6Anomali Incorpora…Ansell Healthcare Products LLC - 10, 15.5Ansell Healthcare…Antenna79, Inc. - 10, 12.9Antenna79Apiqe Holdings, LLC - 10, 18.7Apiqe HoldingsAneira Pharma, Inc. - 10, 23Aneira Pharma
Aneira vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Aneira's grants concentrate

Aneira Pharma, Inc. is a focused PatentsView assignee: 3 CPC subclasses with 100% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2021 (3 grants) versus a trough of 1 in 2024. By volume, Aneira sits between Amylyx Pharmaceuticals, Inc. and Apiqe Holdings, LLC.

Aneira's three-year grant acceleration

Aneira Pharma, Inc. shows 6 grants in 2022–2024 against only 3 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Who files at Aneira's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows Aneira holds 10 patents at rank #25,788, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near Aneira

By rank, the assignees closest to #25,788 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Aneira's primary technology class.

Aneira's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

42 Top 33% higher than 67% of 49,997 US assignees

This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

0.511.522.533.5 20212022202320242025 1
USPTO utility patent grants by year · 2021–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2021–2019 baseline. Full figures in the table below.

View data table
Aneira Pharma, Inc. patent grants by year, 2015–2025
Year Patents Granted Share of Period
2021 3 30.0%
2022 2 20.0%
2023 3 30.0%
2024 1 10.0%
2025partial year 1 10.0%

Which technologies does Aneira Pharma, Inc. patent most?

Top 3 of 3 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Aneira Pharma, Inc.'s patent record in context - here's where to go next.

  • Aneira Pharma, Inc.'s lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 100% of its portfolio - see every assignee active in that class. Explore A61P
  • Ranked #25,739 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
  • Compare Aneira Pharma, Inc. against Amylyx Pharmaceuticals, Inc., an assignee filing at a similar volume. Compare portfolios
  • Innovation Score of 41.5/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page
  • USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
  • Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
  • USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.